A Study of Subcutaneous Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia
NCT ID: NCT00642668
Last Updated: 2017-07-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
35 participants
INTERVENTIONAL
2008-06-30
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.
NCT00462384
A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis
NCT00642967
STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
NCT00642850
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.
NCT00048048
A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.
NCT00364832
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Methoxy Polyethylene Glycol-Epoetin Beta
Participants received methoxy polyethylene glycol-epoetin beta treatment monthly for 36 weeks with an efficacy evaluation period (EEP) during weeks 29-36 and followed by a 4 week follow-up period.
methoxy polyethylene glycol-epoetin beta
1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
methoxy polyethylene glycol-epoetin beta
1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chronic renal anemia;
* No ESA therapy during previous 3 months.
Exclusion Criteria
* Poorly controlled hypertension requiring hospitalization in previous 6 months;
* Significant acute or chronic bleeding.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UZ Leuven Gasthuisberg
Leuven, , Belgium
Chr de La Citadelle
Liège, , Belgium
CHU Sart-Tilman
Liège, , Belgium
Clinique Saint-Joseph
Liège, , Belgium
AZ Delta (Campus Wilgenstraat)
Roeselare, , Belgium
AZ Nikolaas (Sint Niklaas)
Sint-Niklaas, , Belgium
CHWapi site IMC
Tournai, , Belgium
AZ Turnhout Sint Jozef
Turnhout, , Belgium
CHR de Verviers - East Belgium
Verviers, , Belgium
ZOL (Sint Jan)
Genk, , Belgium
AZ Sint Lucas (Sint Lucas)
Ghent, , Belgium
UZ Gent
Ghent, , Belgium
CH EpiCURA Site Hornu
Hornu, , Belgium
CHR Hutois
Huy, , Belgium
Jan Yperman Onze Lieve Vrouw
Ieper, , Belgium
ASZ Aalst
Aalst, , Belgium
ZNA Middelheim
Antwerp, , Belgium
ZNA Stuivenberg
Antwerp, , Belgium
AZ Sint Lucas Brugge
Assebroek, , Belgium
CH EpiCURA Site Ath
Ath, , Belgium
CH EpiCURA Site Louis Caty
Baudour, , Belgium
Imeldaziekenhuis
Bonheiden, , Belgium
Clinique Saint-Jean- Botanique
Brussels, , Belgium
CHU Brugmann (Victor Horta)
Brussels, , Belgium
Clin Univ de Bxl Hôpital Erasme
Brussels, , Belgium
HIS (Joseph Bracops)
Brussels, , Belgium
UZ Brussel
Brussels, , Belgium
CHIREC Edith Cavell
Brussels, , Belgium
Cliniques Universitaires St-Luc
Brussels, , Belgium
CHU de Charleroi
Charleroi, , Belgium
AZ Sint Blasius (Dendermonde)
Dendermonde, , Belgium
UZ Antwerpen
Edegem, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML21348
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.